Recently, an engineered fusion protein, TIGIT-Fc-LIGHT, the linkage between the extracellular domain of TIGIT and the extracellular domain of TNFSF14, was reported to show anti-tumor activity in pre-clinical models, especially in those who were resistant to anti-PD-1 treatment [129]. The gene discussed is TIGIT; the disease is neoplasm.